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Background: The National Cervical Screening Program in Australia currently recommends that women aged 18–69
years are screened with conventional cytology every 2 years. Publicly funded HPV vaccination was introduced in
2007, and partly as a consequence, a renewal of the screening program that includes a review of screening
recommendations has recently been announced. This study aimed to provide a baseline for such a review by
quantifying screening program resource utilisation and costs in 2010.
Methods: A detailed model of current cervical screening practice in Australia was constructed and we used data
from the Victorian Cervical Cytology Registry to model age-specific compliance with screening and follow-up. We
applied model-derived rate estimates to the 2010 Australian female population to calculate costs and numbers of
colposcopies, biopsies, treatments for precancer and cervical cancers in that year, assuming that the numbers of
these procedures were not yet substantially impacted by vaccination.
Results: The total cost of the screening program in 2010 (excluding administrative program overheads) was
estimated to be A$194.8M. We estimated that a total of 1.7 million primary screening smears costing $96.7M were
conducted, a further 188,900 smears costing $10.9M were conducted to follow-up low grade abnormalities, 70,900
colposcopy and 34,100 histological evaluations together costing $21.2M were conducted, and about 18,900
treatments for precancerous lesions were performed (including retreatments), associated with a cost of $45.5M for
treatment and post-treatment follow-up. We also estimated that $20.5M was spent on work-up and treatment for
approximately 761 women diagnosed with invasive cervical cancer. Overall, an estimated $23 was spent in 2010 for
each adult woman in Australia on cervical screening program-related activities.
Conclusions: Approximately half of the total cost of the screening program is spent on delivery of primary
screening tests; but the introduction of HPV vaccination, new technologies, increasing the interval and changing
the age range of screening is expected to have a substantial impact on this expenditure, as well as having some
impact on follow-up and management costs. These estimates provide a benchmark for future assessment of the
impact of changes to screening program recommendations to the costs of cervical screening in Australia.Background
The National Cervical Screening Program (NCSP) in
Australia commenced in 1991 and is a joint program of
the federal Australian Government and individual state
and territory governments [1,2]. The NCSP recommends
cervical screening every 2 years for sexually active* Correspondence: karenc@nswcc.org.au
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reproduction in any medium, provided the orwomen from age 18–20 years up to 69 years [3]. Women
with abnormal cytology are followed-up with repeat cy-
tology or referred for diagnosis using colposcopy and bi-
opsy (if indicated), with the follow-up time for cytology
or decision to refer depending on the severity of the ab-
normal cytology and a woman’s screening history and
age [4]. Treatment is recommended for women diag-
nosed with histologically-confirmed high-grade cervical
intraepithelial neoplasia (CIN 2/3) [4]. Post-treatment
“test-of-cure” management is recommended for women
previously treated for high-grade precancerous lesions,
commencing 12 months after the treatment until the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(HPV) testing and cytology on two consecutive occa-
sions [4]. In 2010, the age-standardised screening pro-
gram participation rates over the previous 2 years, 3
years and 5 years among eligible women aged between
20 and 69 years were 57.4%, 70.2% and 83.3% [5]. Par-
ticipation was highest among women aged between 30
and 64 years, but was lower in younger and older
women within the target age range (18–69 years) [5].
Cervical cancer incidence and mortality rates in Austra-
lia have reduced by over 50% since the introduction of
organised screening to 6.8 and 1.8 per 100,000 women,
respectively in 2007 [5].
The National HPV Vaccination Program in Australia
commenced in 2007. This comprises a school-based pro-
gram, generally targeting girls in the first year of high-
school (approximate age 12–13 years), and a catch-up
program, running until the end of 2009, which provided
vaccination for females aged between 13 and 26 years.
Vaccination coverage in females aged between 18 to 26
years over the course of the catch-up program was be-
tween 30 and 38% for the full three-dose course [6]. In
2010, the oldest women in the catch-up cohort were
aged 29 years. Many of the women in the catch-up co-
hort were expected to have participated in the cervical
screening program.
Initial ecological data show an apparent early effect of
vaccination in reducing high grade abnormalities in
2009–2010 in women less than 18 years, but not yet in
older age groups [5,7]. There is expected to be a reduced
risk of high grade abnormalities and invasive cervical
cancer in young vaccinated women, and this has
prompted consideration of increasing the age of starting
screening. Even prior to the advent of vaccination, an
increased screening interval and a later age of starting
screening are supported by a large body of international
evidence [8-10]. A process of Renewal (review) of the
NCSP in Australia was announced in November 2011
[11]; this will involve considering new technologies, and
reviewing the interval and age range of screening; if
changes are implemented this would be expected to have
a substantial impact on screening program costs. This
study aimed to use a calibrated and validated model to
provide a benchmark for future changes to the cervical
screening program by quantifying screening program
resource utilisation and costs in the year 2010.
Methods
A deterministic Markov model, coupled with a dynamic
model of HPV transmission, was constructed to simulate
cervical screening in Australia. This single and multiple
cohort model platform, adaptable to different settings,
has been previously used to evaluate changes to the
cervical screening interval in Australia and UnitedKingdom [12,13], to assess the role of alternative technolo-
gies for primary screening in Australia, New Zealand, and
England [14,15], to assess the role of HPV triage test-
ing for women with low-grade cytology in Australia
and New Zealand [16],to assess the role of HPV test-
ing in post-treatment management for women treated
for CIN [15,17] and to evaluate the cost-effectiveness
of alternative screening strategies and combined
screening and vaccination approaches in rural China
[18,19]. The dynamic model of HPV transmission is
implemented in Microsoft Visual C++, and the Markov
model is implemented in TreeAge Pro 2008 (Release 1.3.2,
TreeAge Software, Inc., MA, USA), with a Microsoft Office
Excel interface integrated with Visual Basic for multiple
cohort implementations.
In this study, we modelled the natural history of HPV in-
fection and CIN to simulate the progression and regres-
sion of women’s underlying health state of those infected
with HPV. A woman’s screening outcome was modelled as
the interaction between the test characteristics of the
screening/diagnostic test (the positivity rate for each
underlying health state) and the woman’s true underlying
health state. Disease recurrence was modelled as women’s
underlying health state progression from a no CIN state to
CIN2+ after treatment at a specific annual rate. Recurrent
CIN2+ could be detected during a visit, depending on the
test characteristics of the screening/diagnostic test [14,16].
More details of model’s structure, assumptions and data
source used are described in the following sections.
Model of the natural history of HPV, precancer and
cervical cancer
The natural history model simulates the development of
cervical precancer and invasive cervical cancer in
cohorts of women in Australia. The age-specific HPV in-
cidence is obtained from a dynamic model of HPV
transmission in Australia, [20,21] which simulates the
natural history of HPV in females of all ages, using sur-
vey data on sexual behaviour in the community to pre-
dict HPV incidence by single year of age. The natural
history model was adapted from a previously published
model [12] and, after including screening and manage-
ment (see below), was calibrated to Australian data on
the age-specific prevalence of oncogenic HPV in
cytologically-normal women, observed rates of histologi-
cally confirmed high-grade lesions, and cervical cancer
age-specific incidence and mortality rates [13,14,16]. The
age-standardised annual progression rate from CIN3 to
asymptomatic localised cancer was calibrated to be 1.3%,
consistent with the available data [22].
Model of cervical screening, diagnosis and treatment
The details of the structure, assumptions, and the data
source used in the Australia screening model have
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component in the model was constructed according
to current management guidelines for women with
screen-detected cervical abnormalities in Australia [4].
The model contains detailed structures for modelling
the management of cervical abnormalities. Briefly,
women with a high-grade cytology result are referred
for colpsocopic assessment; women with a low-grade
cytology result are referred for further colposcopic as-
sessment if they are found to have a recent (in the
past 24 months) low-grade or worse cytology result
or if the women is older than 30 years and has no
history of negative cytology in the previous 2 years,
otherwise, a 12 months follow-up with cytology test
is recommended; women with negative cytology result
are referred to have a follow-up cytology test at 12
months if they had a recent low-grade or worse cy-
tology result, otherwise a 2-yearly routine screening is
recommended [4]. Post-treatment management was
modelled according to the recommendations of the
relevant national guidelines [4]. The guidelines recom-
mend that women treated for high-grade CIN are
followed-up at 4–6 months after treatment with cytology
and colposcopic examination, and then undergo annual
follow-up with cytology and HPV testing, starting from
12 months after treatment, until they have tested nega-
tive by both cytology and HPV test on two consecutive
occasions. The model takes into account the age distri-
bution of starting screening and observed age-specific
screening behaviour for women aged 18 years and older
(including screening occurring in women older than the
target age of screening); this was informed by analysis of
data from the period 1997–2007 from 6.3 million satis-
factory cytology tests from the Victorian Cervical Cy-
tology Registry (VCCR). By directly modelling observed
behaviour, the model captures the costs and effects due
to both early re-screening and any late re-screening in
different age groups.
The test characteristics for conventional cytology and
HPV testing (currently used as a test-of-cure), were
obtained from systematic reviews of the literature and
were consistent with local observed data on cytology call
rates [14]. Test characteristics for colposcopy were based
on an analysis of the colposcopy-histology correlation
from a database of approximately 21,000 colposcopies
conducted in Victoria [14,16]. The failure rate of treat-
ment for high grade CIN, and post-treatment recurrence
rates were obtained from a meta-analysis of the inter-
national literature [14,16]. Stage-specific cervical cancer
survival used in the model was derived from registry
data from the state of New South Wales [14,16]. Age-
specific deaths from causes other than cervical cancer
were calculated using all-cause mortality after subtract-
ing the cervical cancer mortality rate [23].Cost collation
Medicare, Australia’s universal health care system, reim-
burses procedures included on the Medicare Benefits
Schedule (MBS). A health services perspective was taken
in this study, considering only the costs to government
related to screening, referral, diagnosis, treatment and
follow-up of cervical abnormalities and the treatment of
cervical cancer; overheads related to administration and
promotion of the screening program, incentives to prac-
titioners, and women’s out-of-pocket costs were not
included.
Costs for screening, diagnostic and treatment proce-
dures were derived with the aid of an expert advisory
panel to the Medical Services Advisory Committee
(MSAC) [14,16] based on current clinical practice and
the item cost of the component services, which were
obtained from MBS Online (2010) for outpatient med-
ical services [24], National Hospital Cost Data Collection
Round 13 (2008–09, public) for inpatient services [25]
and the Pharmaceutical Benefits Schedule (PBS) Online
(August 2008) [26] where applicable. The advisory panel
comprised members/nominees from the Department of
Health of the federal and state governments, the Royal
Australian and New Zealand College of Obstetricians
and Gynaecologists, the Royal College of Pathologists of
Australia, the Royal Australian College of General Prac-
titioners, the Australian Society of Cytology, and Consu-
mers. The final methods and costs used were reviewed
and approved by the panel.
We have previously described the methods for ag-
gregating costs related to cervical screening in Austra-
lia in 2008 [14,16]. In the current study, we updated
the item costs to 2010 and calculated aggregate costs
using the same methods as previously described.
Table 1 shows the summary of aggregate costs used
by the model; full details of calculation of the aggre-
gate costs are provided in the Additional file (See
Additional file 1: Table S1-S10).
The aggregate cost of cytology comprised a medical
consultation cost and a pathology cost. The consultation
cost takes into account the range of practitioners who
can collect cytology samples, and also that the purpose of
consultation may be for multiple reasons. In the case
where a second cytology test is performed after an unsa-
tisfactory test, we assumed that the full cost of GP/
specialist consultations was applicable. Abnormal cyto-
logy results were assumed to incur an additional consul-
tation cost for conveying to the woman the cytology
result. The model also assumed that a cytology test was
performed during 85% of colposcopy visits, based on data
from a large colposcopy database [14,16]. In Australia,
currently the Medicare rebate for cytology test is the
same regardless of whether or not the women comply
with the recommended screening or follow-up interval.
Table 1 Aggregated cost data used in the model of cervical screening in Australia, 2010 (see Additional file 1 for
associated cost items)
Cost item Calculated
aggregated
cost in 2010
Itemised costs contained in the
aggregated cost
Data sources
Cost of screening with cytology test
Having a cytology test alone
(including $19.60 for cytology test)
$58.05 A weighted average cost of consultation,
a cost of cytology test and a PEI
MBS online database 2010 [24]
and Britt et. al. 2010 [27]
Having a cytology test after an
unsatisfactory test
$67.23 An average cost of consultation,
a cost of cytology test and a PEI
MBS online database 2010 [24]
Cost of abnormal cytology follow-up
Abnormal cytology test result
consultation and gynaecologist referral
$39.38 An average cost of consultation MBS online database 2010 [24]
and Britt et. al. 2010 [27]
Having a colposcopy without biopsy $143.75 A cost of specialist consultation
and a colposcopy
MBS online database 2010 [24]
Having a colposcopy with biopsy $295.98 A cost of specialist consultation,
a colposcopy, a biopsy and PEI
MBS online database 2010 [24]
Having a colposcopy without biopsy
(with a cytology sample taken)
$171.60 A cost of specialist consultation,
a colposcopy, a cytology test and a PEI
MBS online database 2010 [24]
Having a colposcopy with biopsy
(with a cytology sample taken)
$315.58 A cost of specialist consultation,
a colposcopy, a biopsy, a cytology and PEI
MBS online database 2010 [24]
Cost of treating a precancerous lesions and follow-up women treated for CIN2/3
Treatment for precancerous lesions $1,263.23 A weighted average cost of various
high-grade lesions treatment procedures
including ablation therapy, excision
therapy and hysterectomy
MBS online database 2010 [24]
and DRG [25]
Follow-up for women treated for
CIN 2/3 at 4–6 months after treatment
(using cytology test and colposcopy)
$130.65 A cost of specialist consultation,
a cytology, a colposcopy and PEI
MBS online database 2010 [24]
Follow-up for women treated for CIN 2/3
at 12/24 months after treatment
(using cytology test and HCII)
$131.23 A weighted average cost of consultation,
a cytology, a HPV testing and PEI
MBS online database 2010 [24]
Cost of work–up for cancer diagnosis
Localised cancer $1,820.98 A weighted average cost of various
cancer work-up diagnosis procedures
including colposcopy, chest x-ray,
CT scan, PET scan, MRI,
bone scan and cystoscopy.
MBS online database 2010 [24],
DRG [25] and expert opinions [14,16]
Regional cancer $2,007.69
Distant cancer $1,979.24
Cost of cancer treatments †
Localised cancer treatment $13,115.93 A weighted average cost of surgical
(conisation, hysterectomy, radical
hysterectomy and exenteration)
and non surgical treatments
(radiationtheraphy, adjuvant radiation
therapy and chemo-radiation)
received by cancer patients.
MBS online database 2010 [24],
DRG [25], and expert opinions [14,16]
Regional cancer treatment $32,048.22
Distant cancer treatment $24,250.30
Terminal care $24,250.30 Assumption
PEI, Patient episode initiation; MBS, Medical benefit schedule; DRG, diagnosed-related group; CIN2/3, cervical intraepithelial neoplasm grade 2 or 3; HCII, Hybrid
Capture II.
† The weighted average cost of cancer treatment was derived from the cost data by FIGO stage, which was grouped to broadly represent the extent of disease
categories. The cost of cancer treatment varies significantly between FIGO 1a1 ($7,330.55), 1a2 ($13,164.32), 1b2 ($16,270.50) and the more advanced stages
($24,250.30-$32,458.30). See Additional file 1: Table S7–S10 for further details of the calculation of cancer treatment costs.
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composed of the weighted-average of the costs of abla-
tional treatment, excisional treatment and hysterectomy.
The weighting for each treatment type was informed by
Medicare data on the number and type of treatments
claimed in 2010, which was obtained from the MBS on-
line database, [28] and an analysis of a large colposcopydatabase [14,16]. In the model, women treated for high-
grade lesions attended for cytology and colposcopy
within 6 months after treatment. The model assumes
that in 6.4% of these women, initial treatment was un-
successful and a second treatment was required, with a
further follow-up visit 6 months later [14,16]. Women
treated for high grade CIN lesions were assumed to be
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ing with cytology and HPV testing, starting from 12
months after treatment until the women tested negative
for both tests on two consecutive occasions [4].
All cancer treatment costs, including the costs in-
curred in the year when cancer was diagnosed and the
costs incurred over the subsequent years were applied as
a one-off cost in the year of diagnosis, with the excep-
tion of terminal care costs which were applied in the
year a patient died from cervical cancer. The distribution
of cancer stage at diagnosis was based on data provided
by the Queensland Gynaecological Cancer Centre and
the Royal Women’s Hospital, Melbourne [14,16]. The
data were provided according to International Feder-
ation of Gynecology and Obsterics (FIGO) stage and
were then grouped to represent disease extent categor-
ies, consistent with the model’s structure. No national
data were identified to inform the types and frequencies
of procedures used for work-up and treatment for cer-
vical cancer, therefore expert opinion was sought. The
stage–specific work-up costs and cancer treatment costs
were a weighted average of the relevant procedures,
which were also based on expert opinion, as previously
described [14,16].
Model outcomes and comparison against observed data
The outputs of the model included age-specific pre-
dicted cost and rates of cytology test utilisation, colpos-
copies, biopsies, treatment for precancerous lesions,
cancer incidence and cancer mortality. The model out-
puts for the annual number of cytology tests, numbers
of histologically confirmed high grade lesions detected,
and case numbers for incident cervical cancer and cer-
vical cancer deaths have been previously validated by
comparing against observed data [13,14,16,23,29]. For
the current evaluation, we updated the population struc-
ture using the 2010 Australian female resident popula-
tion [30]. We then compared updated predictions for
the number of cytology tests against recent data [5]. Be-
cause cancer incidence and mortality data for the year
2010 were not yet available at the time of writing, popu-
lation structures for the years 2004–2007 were applied
for the purposes of comparing model outputs against
observed age-specific cancer cases and deaths only, dur-
ing which period the cervical cancer rates and mortality
rates were relatively stable (at the time of writing, 2007
was the latest year where both the national cervical can-
cer incidence and death rates were publicly available).
We then used the model to estimate the expenditure
and resource utilisation in the NCSP in 2010, including
the cost and number of cervical screening tests, colpos-
copies, biopsies, treatments for precancerous lesions,
post-treatment tests, cancer treatments, incident cervical
cancer cases and cancer deaths. We also calculated theaverage per-woman costs related to cervical screening,
diagnosis and treatment; firstly, per woman in the popu-
lation and secondly, per woman participating in the
screening program in that year, for adult women aged
18–84 years (in 2010, Australia had 8.5 million resident
women aged between 18–84 years and more than 3.6
million women participated in NCSP over the 2 year
period 2009-2010 [5,30]). The latter calculation takes
into account that lower costs in some age groups may
be due to lower coverage.
The model was also used to estimate expenditure, inci-
dent cancer cases and cancer deaths under the hypothet-
ical scenario that no cervical screening had occurred.
The estimated cost per incident cervical cancer case pre-
vented and cost per cancer death prevented in 2010
were then calculated. The cost per life-year saved asso-
ciated with current screening vs. no screening was also
calculated. Costs and life-years were calculated from age
18 (the earliest age at which screening is recommended
to start in Australia) with discounting at a rate of 5%.
All costs are presented in 2010 Australian dollars ($A1 =
$US0.85634 as at June 30, 2010).
Sensitivity analysis
Sensitivity analyses were performed to assess the robust-
ness of predicted expenditure to a subset of screening,
cost and natural history parameter assumptions applied
in the model. For the screening parameters, we exam-
ined the sensitivity of the model’s predictions to the
assumptions around screening attendance and compli-
ance with recommendations, the unsatisfactory rate of
cytology and colposcopy, and test characteristics of cy-
tology and colposcopy. For the aggregated unit cost
parameters, alternate costs of treatment for precancer-
ous lesions, cancer diagnosis and treatment and a lower
85% MBS reimbursement level were assessed. The sensi-
tivity of the model’s prediction to a key natural history
assumption was also assessed by halving and doubling
the non-symptomatic invasive cancer progression
probabilities.
Ethical approval
Screening registry data, colposcopy data and other
sources of data used in the model were de-identified,
and the Cancer Council NSW Human Research Ethics
Committee approved the transfer of these datasets to
the researchers and their use in this modelled
evaluation.
Results
Model predictions for 2010 and recent observed data
reported in Australia are summarised in Table 2. How-
ever, it should be noted that at the time of writing data
for 2010 were not yet available for some screening
Table 2 Model outcomes in Australia 2010, compared against latest observed data
Model predicted Latest observed data†
Number of cytology performed
20-69 years 2 million 2 million
All ages 2.1 million 2.1 million
Number of low-grade cytology abnormalities detected in women 20–69 years 84,600 78,510††
Number of high-grade cytology abnormalities detected in women 20–69 years 27,700 28,491††
Number of women with abnormal cytology with a follow-up histological evaluation 33,200 38,859††
High-grade histology rate per 1,000 women screened 7.4 8.4
Age-standardised rate of cervical cancer incidence per 100,000 women‡
20-69 years 8.9 9.3‡‡
All ages 6.6 7‡‡
Age-standardised rate of cervical cancer incidence per 100,000 women‡
20-69 years 2.1 1.9‡‡
All ages 1.8 1.8‡‡
† Data obtained from Cervical Screening in Australia 2009–2010 report [5].
†† At the time of writing the latest available data was in 2009.
‡ Age-standardised to 2001 Australian population.
‡‡ At the time of writing the latest available data for cancer incidence was in 2008 and for cancer mortality was 2007.
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which incorporate 2010 population information cannot
be directly compared to the data for earlier years since
the population structure and size changes over time.
Overall costs and resource utilisation
The model estimated that the total expenditure for cer-
vical screening program in 2010 was $194.8 million. Of
this, the model predicted that 55% (~$107.6 million) was
spent on cytology testing for routine cervical screening
among women without a recent history of cervical ab-
normalities (within two years) and for follow-up of
women with recent low-grade abnormalities. A further
11% (~$21.2 million) was spent on diagnostic0
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Figure 1 Program cost by age and expenditure type, Australia 2010.
published by Australia Institute of Health and Welfare (AIHW) in 2011 [5].procedures to follow-up abnormal cytology results, in-
cluding colposcopies, cytology performed at colposco-
pies and biopsies; 23% (~$45.5 million) was spent on
treatment for precancerous lesions and to provide post-
treatment follow-up for “test-of-cure” management with
cytology and HPV tests; and 11% (~$20.5 million) was
spent on work-up and treatment for women diagnosed
with invasive cervical cancer.
Figure 1 shows the estimated program expenditure by
age and expenditure type, and women’s participation in
NCSP over the 2-year period 2009–2010 (participation
data obtained from the annual report published by the
Australia Institute of Health and Welfare [5]). Screening
with cytology comprises the major proportion (~50%) of0
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and treatment for precancerous lesions accounted for
about one third of the expenditure in women aged less
than 25 years (31-37%), but this proportion decreased
gradually in older age groups. The cost of cancer diagno-
sis and treatment contributed less than 1% of the ex-
penditure in women aged <25 years but the percentage
increased in older age groups.
Of the $194.8 million total expenditure in 2010, about
95% (~$185.4 million) was estimated to have occurred in
women aged 18 to 69 years. As shown in Figure 1, the
highest expenditure was estimated to have occurred in
women aged 35–39 years. Approximately half of the
total expenditure (~$88.9 million) occurred between
aged 30 and 49 years. This pattern of expenditure by
age broadly mirrors patterns of participation by age
(Figure 1).
Figure 2 shows the estimated average screening cost in
2010 per woman by age. The estimated overall average
screening cost per woman in the population aged be-
tween 18 to 84 years (including women not screened in
the 2010 calendar year) was $23. As expected, the lowest
average costs were in women outside the target age
range for screening (<$11 in women aged <20 years and
in women aged 70+ years), while the highest average
cost ($27-29) was estimated to occur in women aged
30–49 years. When considering only women who parti-
cipated in screening, and therefore taking into account
coverage, the estimated average annual cost increased to
$102 per adult woman. This varied from $89-$106 per
woman screened or treated for cervical cancer for
women aged between 18–69 years; and was greater than
$150 per woman screened or treated for cervical cancer$0
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Figure 2 Age-specific average annual cervical screening-related expe
screened, Australia 2010.for women older than 70 years. Again, the difference in
this average cost per woman screened or treated for
cervical cancer among age groups is broadly attribut-
able to the screening participation rate in women of
different ages.
Resource utilisation and costs associated with cytology
The model estimated that about 2.1 million cytology
tests were performed in 2010 (including primary screen-
ing tests, repeat tests after an unsatisfactory result, tests
collected during colposcopy and tests conducted for
follow-up of women treated for precancerous lesion) at
a cost of over $118 million in 2010 (Table 3). Of the 2.1
million cytology tests, more than 1.8 million (associated
with a cost of ~$107.5 million) were performed as part
of cervical screening (about 1.7 million cytology tests
were performed among women without recent history of
cervical abnormalities and approximately 188,900 tests
were performed to follow-up women with recent low-
grade abnormalities) and 160,600 cytology tests (asso-
ciated with a cost of ~$10.8 million) were performed for
test-of-cure management of women previously treated
for histologically-confirmed high-grade cervical abnor-
malities. The remaining cytology tests were performed
during colposcopy. About half of the overall cytology-
related costs were incurred among women aged 30–49
years. The direct test cost was estimated to account for
approximately one third of the total, with the remainder
attributable to GP or specialist consultation fees and
additional benefits paid to laboratories.
The model also estimated 87,500 and 28,600 cytology
tests were found to have low-grade and high-grade ab-
normalities respectively in women of all ages in 2010;up (years)
ated for cervical cancer
n
nditure per adult woman in the population and per adult woman
Table 3 Estimated annual number of cytology tests and associated costs (including consultation time and laboratory
costs) by age group, Australia 2010
Age group
(years)
Cytology test conducted
for primary routine
screening†,††
Cytology test conducted
for follow-up of
low-grade
abnormalities††,‡
Cytology test
conducted as part
of "test-of-cure"
management after
treatment for
high-grade CIN††
Overall annual number
of cytology test
(No. of test conducted
for routine screening
or follow-up of
low-grade
abnormalities) ‡‡
Annual cost related to
cytology testing
(cost related to
cytology test
conducted for
routine screening
or follow-up of
low-grade
abnormalities)
%
total
No. of
tests ‡‡
Related
cost
No. of
tests ‡‡
Related
cost
No. of
tests ‡‡
Related
cost
<20 17,800 $1.0 M 600 $32,900 60 $3,900 19,100 (18,400) $1.1 M ($1.1 M) 1%
20-24 167,100 $9.7 M 20,000 $1.2 M 4,100 $0.3 M 201,600 (187,000) $11.2 M ($10.9 M) 9%
25-29 166,900 $9.7 M 28,700 $1.7 M 10,500 $0.7 M 215,900 (195,600) $12.1 M ($11.4 M) 10%
30-49 784,200 $45.7 M 91,300 $5.2 M 76,300 $5.1 M 981,800 (875,400) $56.0 M ($50.9 M) 47%
50-69 482,700 $28.1 M 44,500 $2.6 M 61,200 $4.1 M 600,000 (527,200) $34.8 M ($30.7 M) 29%
70+ * 41,300 $2.4 M 3,900 $0.2 M 8,300 $0.6 M 54,800 (45,200) $3.2 M ($2.6 M) 3%
20-69 1,600,900 $93.2 M 184,400 $10.6 M 152,200 $10.2 M 1,999,200 (1,785,300) $114.1 M ($103.9 M) 96%
0-84 1,660,000 $96.7 M 188,900 $10.9 M 160,600 $10.8 M 2,073,100 (1,848,900) $118.3 M ($107.5 M) 100%
† When attending for primary screening for women without abnormal results from the previous two or more consecutive cytology tests.
†† Repeat smears conducted during colposcopy examination, precancerous lesion treatments and post-treatment follow-up are not included.
‡ Follow-up of cytological low grade abnormality, or of histologically-verified CIN1 or less; or of women referred with a cytological high-grade but with no
abnormality verified at colposcopy/biopsy.
‡‡ Numbers less than 100 are rounded to the nearest 10. Numbers greater than 100 are rounded to the nearest 100.
* Up to 84 years.
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these high-grade abnormalities were found in women
aged 20–69 years.
Resource utilisation and costs associated with diagnostic
evaluations
The model predicted that about 70,900 colposcopy and
34,100 histology evaluations were performed in 2010
(not including multiple biopsies taken at the same col-
poscopy), costing $21.2 million in 2010 (Table 4). ThisTable 4 Estimated annual number of diagnostic evaluations a
by age group, Australia 2010
Age group
(years)
Diagnostic procedures for precancerous lesions
No. of colposcopy
evaluations†,††
No. of histological
evaluations†,††
Related
cost
%
tot
18-20 700 400 $0.2 M 1%
20-24 10,900 5,900 $3.0 M 14%
25-29 10,500 5,700 $2.9 M 14%
30-49 33,900 16,900 $10.2 M 48%
50-69 13,500 4,800 $4.4 M 21%
70+‡‡ 1,400 500 $0.5 M 2%
20-69 68,800 33,200 $20.5 M 97%
0-84 70,900 34,100 $21.2 M 100
† Rounded to the nearest 100.
††Multiple biopsies taken at the same colposcopy were not included.
‡ Includes procedures performed in women without prior confirmation of high-grad
been found to have a low-grade histological outcome.
‡‡ Up to 84 years.includes the cost of specialist visits, colposcopy tests
and associated cytology tests, biopsy tests and other
histopathology-related expenditure. About half of the
costs were incurred in women aged 30–49 years.
Resource utilisation and costs associated with treatment
for precancerous lesions
The model estimated that about 18,900 treatments for
precancerous lesions were performed in 2010, and the
associated costs of treatment and post-treatment follow-nd treatment for precancerous lesions and related costs
Treatment for precancerous lesions and
post-treatment follow-up
Colposcopy to
treatment ratio
al
No. of precancerous
lesion treatments†,‡
Related
cost
%
total
200 $0.3 M 1% 3.2
3,300 $5.2 M 11% 3.3
3,000 $5.5 M 12% 3.5
7,800 $20.1 M 44% 4.3
4,100 $12.8 M 28% 3.3
400 $1.6 M 3% 3.1
18,200 $43.6 M 96% 3.8
% 18,900 $45.5 M 100% 3.8
e disease (e.g. women with unsatisfactory colposcopy findings) who may have
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of specialist consultation, treatment procedures, and
other related procedures (such as the colposcopy visit
where treatment occurs and histopathology), as well as
test-of-cure management. The model predicted that
about 44% of the precancerous treatments and asso-
ciated follow-up cost were incurred among women aged
30–49 years. We also estimated the colposcopy to pre-
cancer treatment ratio, which gives an indication of the
overall efficiency of the screening process in referring
women requiring treatment, where a value closer to one
indicates more efficient referral (Table 4). This was esti-
mated to be 3.8 overall; the highest colposcopy-to-
treatment ratio (4.3) was in women aged 30–49 years
and the lowest ratio (3.5 or less) was in women younger
than 29 years or older than 50 years; the lower ratio in
women under the age of 30 years is assumed to be due,
in part, to the recommendation to repeat annual smears
in women with low grade cytology but without a history
of cervical abnormalities in the last 2 years before refer-
ral to colposcopy [4,5]; this is predicted to result, in this
age group, in women who are referred to colposcopy
being more likely to harbour confirmed high grade
disease.
Resource utilisation and costs associated with cancer
treatment
Table 5 shows, firstly, a comparison of model predictions
for cervical cancer cases and deaths over the period
2004–2007, with observed average case numbers over
the period. Table 5 also shows the predicted number of
cases and deaths after applying the 2010 population
structure. The model estimated that 761 cases and 213
deaths occurred in 2010 overall. The estimated asso-
ciated cost of cervical cancer diagnosis and treatment
was $20.5 million, with 94% of diagnosis and treatment
related costs incurred in women aged over 30 years.Table 5 Estimated annual number of cancer treatments and r
Age group
(years)
Cervical cancer cases
Model predicted† Observed
(average 2004–2007)
Mo
in 2010 Average in
2004-2007
in 201
<20 0 0 1 0
20-24 16 15 11 0
25-29 46 39 41 5
30-49 341 328 338 70
50-69 235 206 208 79
70+ †† 121 115 102 59
20-69 639 588 598 154
0-84 761 703 701 213
† The numbers are rounded.
†† Up to 84 years.Cost per cervical cancer case and death prevented
The model predicted that 2,475 incident cancer cases
and 894 cancer deaths at an associated cost of $75 mil-
lion (for cancer treatment related costs) would have oc-
curred in 2010 in the absence of cervical screening.
Therefore, the number of cases prevented by the current
organised program is estimated to be 1,714 (69% reduc-
tion) and the number of deaths prevented is estimated
to be 681 (76% reduction). It is possible to calculate esti-
mates for cost per cancer and death prevented, as well
as the cost-effectiveness of the screening program over-
all; but these estimates must be interpreted with caution
for several reasons. Firstly, such estimates assume no
change to risk experienced in different age cohorts,
which due to changing patterns of sexual behaviour may
not be the case. Secondly, costs to prevent cancer and
deaths occurring in 2010 were mainly incurred in past
years, due to the inherent delay in cervical cancer devel-
opment. Thirdly, the estimated costs of cancer treatment
in the hypothetical counterfactual scenario of no screen-
ing do not take account of further centralisation of treat-
ment facilities if the burden of disease was higher.
However, bearing in mind these limitations, the esti-
mated cost per case prevented was $69,400, and the esti-
mated cost per death prevented was $174,600 in 2010,
and the estimated incremental cost-effectiveness ratio of
the organised screening program, compared to no
screening, was $33,000 per life-year saved.
Sensitivity analysis
Figure 3 summarise the findings of sensitivity analysis
on the predicted total program expenditure. The model
prediction is found to be most sensitive to assumptions
around screening behaviour. Under the assumption that
all women who participate in the screening program
comply perfectly to the 2-yearly routine screening and
12 months follow-up recommendations, the estimatedelated costs by age group, Australia 2010
Cervical cancer deaths Related
cost in 2010
% total
del predicted† Observed
(average 2004–2007)0 Average in
2004-2007
0 0 $0.0 M 0%
0 1 $0.3 M 1%
4 3 $0.9 M 5%
67 50 $7.7 M 37%
69 76 $7.0 M 34%
57 57 $4.6 M 23%
140 130 $15.8 M 77%
197 187 $20.5 M 100%
150 170 190 210 230 250 270 290 310 330 350
Colpscopy accuracy (baseline assumption vs. perfect accuracy on 
CIN):
Localised cancer treatment cost ( 25% of FIGO 1a1 was assumed to 
treat by hysterectomy and 75% was assumed to treat by 
conisation vs. baseline assumption):
Colpscopy unsatisfactory rate (-20% vs. +20%): 
Colpsocopy referral compliance rate (-10% vs. +10%):
Cytology unsatisfactory rate (1.1% vs. 4.4%):
Localised ,regional and distant cervical cancer diagnosis and 
treatment costs (-20% vs. +20%):
Cytology test characterisitics (alternative sets of TPMs):
Precancerous lesion treatment cost (-50% vs. +20%): 
Age-standardised progression rate of CIN3 to undetected localised 
cancer (0.65% vs. 2.6% p.a):
Medicare reimbursement rate (85% vs. 100%):
Follow-upscreening attendence rate (-10% vs. +10%)†:
Routine screening attendence rate (-10% vs. +10%)†:
Compliance to routine screening and follow-up recommendations 
(baseline assumption vs. perfect compliance)
Program cost in Australian  dollars ($M)
Figure 3 Sensitivity analysis for total program expenditure, Australia 2010. † Cumulative attendance at each interval since last screened to
10 years were varied.
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higher than the base case estimate which modelled the
observed screening behaviour in the population. The
estimated program cost was also somewhat sensitive to
the assumptions about the level of Medicare reimburse-
ment, CIN natural history and precancerous lesion treat-
ment costs, and was found to be moderately sensitive to
assumptions about test characteristics and the unsatis-
factory rate of cytology and colposcopy, cost of cancer
diagnosis and treatment and the compliance with col-
poscopy referral.
Discussion
We have constructed a comprehensive natural history
and cervical screening model, using observed data on ac-
tual screening behaviour, and extensively calibrated and
cross-validated outputs against observed data from the
NCSP in Australia. We estimate that the program cost
to government, excluding administrative overheads, was
approximately $194.8 million in 2010. In total, about
$174.2 million (89%) of the total expenditure was esti-
mated to be associated with the prevention of invasive
cervical cancer (primary screening of asymptomatic
women, follow-up of women with cervical abnormalities,and diagnosis and treatment for women with precancer-
ous lesions). Within this, a total of 1.7 million primary
screening smears costing $96.7 million were estimated
to have been conducted, a further 188,900 smears cost-
ing $10.9 million were conducted to follow-up low grade
abnormalities, 70,900 colposcopy and 34,100 histological
evaluations costing $21.2 million were performed, and
about 18,900 treatments for precancerous lesions were
performed, costing $45.5 million after accounting for
both the treatment and post-treatment follow-up. We
also estimated that $20.5 million (11%) of the total ex-
penditure was associated with work-up and treatment
for the approximately 761 women who were diagnosed
with invasive cervical cancer, and care for the 213
women who died from cervical cancer.
To our knowledge this is the first study that provides
such detailed estimates of resource utilisation in relation
to any organised cervical screening program in a devel-
oped country. The findings of this evaluation provide a
comprehensive source of information on the NCSP
which has not previously been available. Screening his-
tories for women who participate in the cervical screen-
ing program are collected by State and Territory level
Pap test registers [1,2] and the collected data are collated
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to produce annual public reports summarising participa-
tion rates in the program, early re-screening rates, ab-
normalities detected by cytology and histology, cervical
cancer incidence and cervical cancer mortality in
Australia. The most recent report for the period 2009–
2010 contains expanded information on performance
indicators and also includes overall numbers of cytology
and histology tests [5]. However, information on the
detailed breakdown of the indications for cytology test-
ing (primary screening, follow-up, or test-of-cure), and
the resource utilisation associated with colposcopy, bi-
opsy, treatment, and test-of-cure is either not yet uni-
formly collected (as for in the case of colposcopy) or has
not yet been able to be routinely reported. Where com-
parison was possible, we found good agreement between
our findings and the data published by the AIHW. We
estimate that a total of about 2.1 million smears were
performed in 2010, 2 million of these were performed in
women aged 20–69 years; which is consistent with the
number of tests performed in 2010 recently published
by AIHW (2,109,131 in women of all ages and 2,025,860
in women aged 20–69 years) [5]. We estimate that there
were 84,600 and 27,700 cytology tests which were found
to have low-grade and high-grade cervical abnormalities
respectively in women aged 20–69 years, and that
33,200 women with abnormal cytology had a follow-up
histological evaluation. These findings are broadly con-
sistent with the number of cytology tests with an ab-
normal result in 2010 (78,510 tests associated with
low-grade abnormalities and 28,491 tests associated
with high-grade abnormalities), and the number of cy-
tology tests performed which were followed by a histo-
logical evaluation test in 2009 (38,859 tests) published
by AIHW [5].
The previously available information on the cost of
cervical cancer screening in Australia is limited. A 1993
report of the annual cost of the National Cervical
Screening Program to government estimated these costs
as $138 million; [31,32] applying the health services con-
sumer price index [33,34] this is equivalent to $302 mil-
lion in 2010, but it is not clear whether downstream
diagnostic and treatment costs (or overheads costs) were
taken into account in the estimate. Annual reports on
Australia’s national public health expenditure published
by the AIHW have included some information about
expenditure on the cervical screening program in 2007,
the AIHW reported that cervical screening-related
expenditure by federal and state governments was
$113.2 million, with an average expenditure of $5.33
per person (including both males and females) [35].
Of the $113.2 million, 70% ($79.3 million) was spent
by the federal government on screening-associated
costs including incentive payments, Medicare benefitsfor general practitioner consultations, pathology testing
and other benefits related to collecting cytology
samples, and departmental expenses [35,36]. The
remaining $33.9 million was spent by State and Terri-
tory governments on program implementation and
promoting community awareness of the screening pro-
gram [35]. Although the overall estimate includes
some of the direct costs included in our calculations,
and additionally includes overheads and program pro-
motion costs not included in our estimates, it does
not appear to include costs associated with follow-up
and diagnostic management or treatment for precan-
cerous lesions. Therefore the findings are not directly
comparable with our results. In 2005–06, the AIHW
provided an estimate of government expenditure for
women presenting with symptoms indicative of cancer
of $20.1 million, [36] which appears broadly compar-
able with our estimated costs for cancer work-up and
treatment of $21.5 million.
The total expenditure on health goods and services in
Australia in FY2009-10 has been estimated at $121.4 bil-
lion by the AIHW, [37] and therefore our estimate sug-
gests that secondary prevention with cervical screening
comprises approximately 0.16% of the health-related ex-
penditure in Australia. However, our findings represent
an underestimate of the total costs related to cervical
cancer prevention and treatment, for several reasons.
Firstly, the total costs also include costs related to pri-
mary prevention via the implementation of the National
HPV Vaccination Program, which was beyond the scope
of the current evaluation. Secondly, we did not consider
administrative overheads for the screening program,
which may include substantial costs related to imple-
mentation at the State and Territory level as well as
practice incentive payments for screening in women
aged 20–69 years who have not had a cervical smear in
the last four years, and other incentives for practices that
engage with the program and screening registers [38]. In
this study we did not incorporate overhead costs related
to running the screening registries and sending screen-
ing reminder letters. These costs vary from state to state
and are not available in the public domain. They are
not readily amenable to the type of modelled analysis
used in our paper since the overhead costs are not
related to the number of women screened, but are likely
to relate to state-specific infrastructure and funding
arrangements. The NCSP Renewal process includes a
process to explore an option for a real or virtual na-
tional register system [11] and also an option to change
from the current reminder-based system to an invita-
tional system of call and recall. In consequence the ad-
ministrative overheads for the screening program may
potentially change. Additionally, because our evaluation
was conducted from the health-services perspective, we
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consider additional societal costs to women or their
families that may be related to cervical screening. For
example, in the state of NSW, up to 30% of women
choose to have an adjunctive liquid-based cytology
smear, for which they pay out of their own pocket
[14,39], and therefore these costs are incurred outside
the screening program. If a societal perspective was
taken, this cost as well as women’s out-of-pocket
expenses for transportation, lost of productivity, capital
cost and depreciation, and other program operational
costs including regular program overheads, screening
participation incentives, and the costs associated with
awareness and other health promotion campaigns
would need to be included in the evaluation.
Although our findings appear to be in good agreement
with the available data, the predicted levels of resource
utilisation depend on a number of factors. We assessed
screening behaviour in women of various age groups
and with different screening histories over a 10 year
period using data from Victoria (1995–2007), and then
projected forward to estimate behaviour and the conse-
quent resource utilisation in the year 2010. Newer pro-
cesses for management of low grade abnormalities, and
post-treatment management and test-of-cure only began
to be rolled out from mid-2006, [4] and therefore infor-
mation on compliance with these recommendations is
much more limited than is the case for attendance for
routine screening. While we were able to derive compli-
ance estimates based on the data from the VCCR after
the introduction of the updated guidelines, practices and
behaviour may have changed over time. Any differences
between the assumed and actual behaviour will affect
the accuracy of our estimates of resource utilisation in
the program. Additionally, based on data showing that
cervical cancer incidence and mortality rates have stabi-
lised since about 2003–2004, [40] we assumed that rates
in 2010, which were not yet reported at the time of writ-
ing, would be similar to those observed over the period
2004–2007; again, if actual rates are eventually found to
be substantially different from these levels this would
have an impact on the interpretation of our findings. For
the current analysis we also assumed that the
population-based HPV vaccination program, rolled out
in 2007, did not have a discernable impact on the rate of
detected precancerous abnormalities in adult women
(aged 18 years or older) within the screening program by
2010. This assumption is supported by the findings of a
recent study in Victoria, which identified a reduction in
the incidence of histologically-confirmed high-grade
precancerous lesions in females younger than 18 years
by the end of 2009 (which may be an early marker of
the effects of the vaccination program), but identified
no significant effect on the incidence of high gradeabnormalities in women above the age of 18 years at
this stage [7].
As a strength of our analysis, we used extensive
screening data from VCCR to explicitly model for the
heterogeneity of re-screening rates based on measured
covariates for age, time elapsed since last screen and
recommended follow-up after last screen. We did not
model for residual individual-level heterogeneity in the
re-screening rates due to unmeasured covariates, due to
a lack of information on such covariates to the required
level of detail. Given the explicit modelling of covariates
for re-screening rates, we would expect that residual
individual-level heterogeneity to have limited bias on the
measures of cost-effectiveness.
The annual expenditure on cervical screening and
treatment for CIN (excluding cancer treatment-related
expenditure) in Italy, France and UK has previously been
estimated to be €181.5 million (~A$232 million) with an
estimated 6.4 million women screened in 2005 [41],
€196.5 million (~$251 million) with 6.1 million women
screened in 2004 [42] and £157 million (~$249 million)
with 3.4 million women screened in 2006–07 [43], re-
spectively. Our estimates, based on these data, of the
associated estimated annual expenditure on cervical
screening and treatment for CIN per women screened in
Italy (~$36), France (~$41) and UK (~$73) is lower than
the estimated ~$91 per woman screened in Australia
(this estimate excludes a calculated $11 per women in
Australia for cancer treatment, for comparability with
the other estimates). The differences might be due to a
number of factors, and it is not clear in how much detail
the costs in the other evaluations have been modelled.
Some of the factors impacting the comparison, might in-
clude, for example, the differences in screening recom-
mendations (e.g. screening interval and management of
abnormal cytology), screening participation, local screen-
ing and diagnostic test performances, the underlying dis-
ease prevalence in the population and health system
costs.
We have estimated that the average annual cost of
screening per adult woman in the population is $23, and
that a substantial proportion of this is related to delivery
of primary screening tests and follow-up of low grade
cytological abnormalities. In the future, due to the
effects of the National HPV Vaccination Program, it is
expected that the number of cervical abnormalities and
cases of invasive cervical cancer detected by the orga-
nised cervical screening program will decrease as more
vaccinated women enter and age within the screening
program over time. An ongoing body of work will use
the model platform described here to predict the magni-
tude and timing of the impact of the National HPV Vac-
cination Program on resource utilisation in young
women within the screening program, and will also
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tions on resource utilisation, costs, distribution of cancer
stage at diagnosis and the effectiveness of screening. For
example, we have previously used the platform to evalu-
ate the impact of moving to a three-yearly screening
interval under different systems of screening organisa-
tion (reminder-based versus call-and-recall organisation)
[13], finding that three-yearly screening would be cost
saving and would not have a substantial impact on the
number of cervical cancer cases and cancer deaths. On-
going work will also consider the impact of raising the
age of starting screening, and the effect of further
increases in screening interval which could be consid-
ered in conjunction with the implementation of primary
HPV screening [44]. These evaluations, conducted using
the calibrated and validated model platform described in
the current study, are intended to assist policy-making
in designing optimal strategies for cervical cancer pre-
vention in future.
Some changes to screening programs may affect cancer
incidence, but not, to the same degree, mortality because
actions to increase compliance to recommendations may
impact on stage distribution of detected cancers and thus
mortality. Therefore, not only changes in cancer inci-
dence but also changes in stage distribution in relation to
screening and vaccination at different ages should be
evaluated. The current model is calibrated to observed
data on stage at diagnosis, and incorporates heterogen-
eity in screening uptake and compliance with screening
and follow-up recommendations. These aspects of the
model structure will allow some insight in future evalua-
tions into how changes would affect not only numbers of
cancer cases, but also age distribution, stage at diagnosis,
and therefore survival, in women who are unscreened or
underscreened, as well as those who attend regularly or
are overscreened.Conclusions
We estimate that the total expenditure for the NCSP in
Australia in 2010 was $194.8 million (excluding adminis-
trative overheads), and that the corresponding average
annual cost of screening each adult woman in the popu-
lation was $23. Approximately half of the total cost of
the screening program was spent on primary screening
with cytology; but the introduction of HPV vaccination,
new technologies, increasing the interval and changing
the age range of screening are expected to have a sub-
stantial impact on this expenditure, as well as having an
impact on follow-up and management costs. This evalu-
ation provides a benchmark for future assessment of the
impact of HPV vaccination and of potential changes to
screening program recommendations on the resource
utilisation and costs of cervical screening in Australia.Additional file
Additional file 1: Table S1. Average costs of medical consultation.
Table S2. Problems managed per GP encounter – single service
weighting. Table S3. Cost of screening test. Table S4. Cost of diagnostic
procedures. Table S5. Cost of precancerous lesion treatment. Table S6.
Cost post-treatment follow-up after CIN2/3 treatment. Table S7.
Summary work-up and treatment by FIGO stage and disease extension.
Table S8. Summary stage-specific cervical cancer work-up and treatment
costs by FIGO stage. Table S9. Cost of surgical managements for cervical
cancer treatment. Table S10. Cost of non-surgical managements.
Abbreviations
AIHW: Australia Institute of Health and Welfare; CIN 2/3: Histologically-
confirmed high-grade cervical intraepithelial neoplasia; DRG: Diagnosis
related group; FIGO: International Federation of Gynecology and Obsterics;
HPV: Human papillomavirus; MBS: Medical Benefits Schedule; NCSP: National
Cervical Screening Program; PEI: Patient episode initiation;
PBS: Pharmaceutical Benefits Schedule; VCCR: Victorian Cervical Cytology
Registry.
Competing interests
KC, KH, DG, SL and JT declare that they are involved as investigators in a
new trial of primary HPV screening in Australia, which will involve support
from the manufacturers of new test technologies. Other authors declared no
conflict of interest. This study was funded by the National Health and
Medical Research Council Australia (NHMRC Project Grant #1007518) and by
Cancer Council NSW.
Authors’ contributions
JBL led the development of the Australian screening model, performed the
modelling analysis for this evaluation, participated in the analysis of model
outcomes, prepared the tables and figures and participated in drafting the
manuscript. KH prepared cost information for the model and guided the
interpretation of cost outcomes. DG provided screening registry data and
guided interpretation of these data. MS participated in model development,
data analysis, manuscript drafting and was responsible for the collation and
integration of epidemiological data into the model. MC led the analysis of
screening registry data and conceived the basic design of the screening
model. CN participated in model development. JF participated in manuscript
drafting. SD and SL performed systematic review of cytology accuracy for
the model and assisted in the specification of model screening and
management pathways. PC participated in the model development for and
the analysis of screening registry data and test probabilities matrix to inform
cytology accuracy. YJK performed review of precancerous lesion treatment
success rates and post-treatment recurrence rates. JT provided colposcopy
data from a large database collected at Royal Women’s Hospital, Melbourne,
and guided interpretation of these data. KC conceived and led the project,
participated in all aspects of the analysis, and drafted the manuscript. All
authors read and approved the final manuscript.
Authors’ information
Jie Bin Lew BSc (Bioinformatics) MPH, Senior Research Programmer, Cancer
Research Division, Cancer Council New South Wales, Sydney, Australia.
Kirsten Howard PhD, Senior Lecturer, School of Public Health, The University
of Sydney, Sydney, Australia.
Dorota Gertig MBBS (Hons) MHSc ScD FAFPHM, Epidemiologist VCS/Medical
Director VCCR, Victorian Cytology Service.
Megan Smith BE MPH, Cervical Modelling Program Manager, Cancer
Research Division, Cancer Council New South Wales, Sydney, Australia.
Mark Clements PhD, Research Fellow, National Centre for Epidemiology and
Population Health, Australian National University, Canberra, Australia. (Current
position and address: Associate Professor, Department of Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden)
Carolyn Nickson PhD, Research Fellow, Centre for Women’s Health, Gender
and Society, University of Melbourne, Victoria, Australia
Ju-Fang Shi PhD, Research Fellow, Cancer Research Division, Cancer Council
New South Wales, Sydney & School of Public Health, Sydney Medical School,
The University of Sydney, Sydney, Australia
Lew et al. BMC Health Services Research 2012, 12:446 Page 14 of 15
http://www.biomedcentral.com/1472-6963/12/446Suzanne Dyer PhD, Systematic Reviews and Health Care Assessment, NHMRC
Clinical Trials Centre, The University of Sydney, Sydney, Australia.
Sarah Lord MBBS MS (Epi), Epidemiologist, NHMRC Clinical Trials Centre &
The Screening and Test Evaluation Program, The University of Sydney,
Sydney, Australia.
Prudence Creighton BSc, Research Programmer, Cancer Research Division,
Cancer Council New South Wales, Sydney, Australia. (Current address: School
of Public Health and Community Medicine, University of NSW, Sydney,
Australia)
Yoon Jung Kang BA MPH (Hons). PhD candidate, Cancer Research Division,
Cancer Council New South Wales, Sydney, Australia
Jeffrey Tan MBBS MRCOG FRANZCOG, Consultant Gynaecologist, Royal
Women's Hospital, Melbourne, Victoria, Australia
Karen Canfell DPhil, Sydney Rotary Research Fellow, Cancer Research
Division, Cancer Council New South Wales & School of Public Health, Sydney
Medical School, The University of Sydney, Sydney, Australia.Acknowledgements
We thank other members of the working group of “Modellers sans
Frontières” for their contributions to the general model structures used in
this study, particularly Robert Walker, Leonardo Simonella, Michael Caruana
and Ming Xu; and the Australian Medical Services Advisory Committee
Advisory Panel members (Applications 1122/Reference 39) for valuable
expert opinion on model structure and parameters.
Author details
1Cancer Research Division, Cancer Council NSW, 153 Dowling Street,
Woolloomooloo, Sydney, NSW 2011, Australia. 2Screening and Test
Evaluation Program, School of Public Health, University of Sydney, Sydney,
NSW 2006, Australia. 3Victorian Cytology Service, 752 Swanston Street,
Carlton, Melbourne, VIC 3053, Australia. 4National Centre for Epidemiology
and Population Health, Australian National University, Canberra, ACT 2000,
Australia. 5Centre for Women’s Health, Gender and Society, University of
Melbourne, 3/207 Bouverie Street, Carlton, Melbourne 3053, Australia.
6School of Public Health, Sydney Medical School, University of Sydney,
Sydney, NSW 2006, Australia. 7NHMRC Clinical Trials Centre, University of
Sydney, Locked bag 77, Camperdown, Sydney, NSW 1450, Australia. 8Royal
Women’s Hospital, Melbourne, Locked Bag 300, Grattan St & Flemington Rd,
Parkville, Melbourne, VIC 3052, Australia. 9Present address: Department of
Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12 A,
P.O. Box 281SE-171 77, Stockholm, Sweden. 10Present address: School of
Public Health and Community Medicine, University of NSW, Sydney, Australia.
Received: 5 June 2012 Accepted: 21 November 2012
Published: 5 December 2012References
1. Australian Government Department of Health and Ageing National Cervical
Screening Program: Pap test register. Available at: http://www.
cancerscreening.gov.au/internet/screening/publishing.nsf/Content/register.
[Last accessed 13 April 2011]
2. Australian Institute of Health and Welfare (AIHW): Cervical Screening in
Australia 2007–2008: data report. Cancer series no. 54. Cat. no. CAN 50.
Canberra: AIHW; 2010.
3. Australian Government Department of Health and Ageing National Cervical
Screening Program: About the program. Available at: http://www.
cancerscreening.gov.au/internet/screening/publishing.nsf/Content/
cervical-about. [Last accessed 12 April 2011]
4. National Health and Medical Research Council: Screening to Prevent Cervical
Cancer: Guidelines for the Management of Asymptomatic Women with Screen
Detected Abnormalities. Canberra: Commonwealth of Australia; 2005.
5. Australian Institute of Health and Welfare (AIHW): Cervical screening in
Australia 2009–2010. Cancer series 67. Cat. no. CAN 63. Canberra: AIHW; 2012.
6. Australia Government Department of Health and Ageing: Human
Papillomavirus (HPV). Available at: http://www.immunise.health.gov.au/
internet/immunise/publishing.nsf/Content/immunise-hpv.
[Last accessed 11 July 2011]
7. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early
effect of the HPV vaccination programme on cervical abnormalities in
Victoria, Australia: an ecological study. Lancet 2011, 377:2085–2092.8. IARC Working Group on the Evaluation of Cancer: IARC Handbooks of Cancer
Prevention Volume 10: Cervix Cancer Screening. Lyon: IARC Press; 2005.
9. Sasieni P, Adams J, Cuzick J: Benefit of cervical screening at different
ages: evidence from the UK audit of screening histories. Br J Cancer 2003,
89:88–93.
10. Sasieni P, Castanon A, Cuzick J: Effectiveness of cervical screening with
age: population based case–control study of prospectively recorded
data. BMJ 2009, 339:b2968.
11. Australian Government Department of Health and Ageing: National Cervical
Screening Program Renewal. Available at: http://www.health.gov.au/internet/
screening/publishing.nsf/Content/ncsp-renewal. [Last accessed 1 May 2012]
12. Canfell K, Barnabas R, Patnick J, Beral V: The predicted effect of changes in
cervical screening practice in the UK: results from a modelling study.
Br J Cancer 2004, 91:530–536.
13. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, Lord S,
Canfell K: Cervical cancer screening in Australia: modelled evaluation of
the impact of changing the recommended interval from two to three
years. BMC Public Health 2010, 10:734.
14. Medical Services Advisory Committee: Automation Assisted and Liquid Based
Cytology for Cervical Cancer Screening. MSAC reference 1122, Assessment
report. Canberra: Commonwealth of Australia; 2009.
15. Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A,
Sadique Z, Moss S, MAVARIC Trial Study Group: MAVARIC - a comparison
of automation-assisted and manual cervical screening: a randomised
controlled trial. Health Technol Assess 2011, 15:iii–xi. ix-xi,1-170.
16. Medical Services Advisory Committee: Human Papillomavirus Triage Test For
Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions.
MSAC reference 39, Assessment report. Canberra: Commonwealth of Australia;
2009.
17. Legood R, Smith MA, Lew JB, Walker R, Moss S, Kitchener H, Patnick J,
Canfell K: Cost effectiveness of human papillomavirus test of cure after
treatment for cervical intraepithelial neoplasia in England: economic
analysis from NHS sentinel sites study. BMJ 2012, 345:e7086.
10.1136/bmj.e7086.
18. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R,
Smith MA, Nickson C, et al: Prevention of cervical cancer in rural China:
evaluation of HPV vaccination and primary HPV screening strategies.
Vaccine 2011, 29:2487–2494.
19. Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, Ning Y, Simonella L, Ma L,
Kang YJ, Zhang YZ, et al: Evaluation of primary HPV-DNA testing in
relation to visual inspection methods for cervical cancer screening in
rural China: an epidemiologic and cost-effectiveness modelling study.
BMC Cancer 2011, 11:239.
20. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV: The predicted
impact of vaccination on human papillomavirus infections in Australia.
Int J Cancer 2008, 123:1854–1863.
21. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K: The
predicted impact of HPV vaccination on male infections and male
HPV-related cancers in Australia. Vaccine 2011, 29:9112–9122.
22. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg
DC: Natural history of cervical neoplasia and risk of invasive cancer in
women with cervical intraepithelial neoplasia 3: a retrospective cohort
study. Lancet Oncol 2008, 9:425–434.
23. Australian Institute of Health and Welfare (AIHW): ACIM (Australian Cancer
Incidence and Mortality) Books. Canberra: AIHW; 2010.
24. Australian Government Department of Health and Ageing: MBS online:
Medicare Benefits Schedule. Available at: http://www.mbsonline.gov.au/
internet/mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-
MBS-1. [Last accessed 1 May 2012]
25. Commonwealth Department of Health and Aged Care: National Hospital
Cost Data Collection: Cost report Round 13 (2009–2009). Canberra:
Commonwealth of Australia; 2010.
26. Australian Government Department of Health and Ageing: Pharmaceutical
Benefits Scheme (PBS). Available at: http://www.pbs.gov.au/pbs/home.
[Last accessed 1 May 2012]
27. Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, Valenti L,
Harrison C, O'Halloran J, Fahridin S: General practice activity in Australia
2009–10. General practice series no. 27. Cat. no. GEP 27. Canberra: AIHW; 2010.
28. Australian Government Medicare Australia: Medicare Item Report. Available
at: https://www.medicareaustralia.gov.au/statistics/mbs_item.shtml. [Last
accessed 1 May 2012]
Lew et al. BMC Health Services Research 2012, 12:446 Page 15 of 15
http://www.biomedcentral.com/1472-6963/12/44629. Royal College of Pathologists Australasia Cytopathology Quality Assurance
Programs (RCPA QAP): Performance Standards for Australian Laboratories
Reporting Cervical Cytology 2008. New South Wales: RCPA QAP; 2008.
30. Australia Bureau of Statistics: Australian demographic statistics, September
Quarter 2010. Canberra: Commonwealth of Australia; 2011.
31. Farnsworth A, Mitchell HS: Prevention of cervical cancer. Med J Aust 2003,
178:653–654.
32. Commonwealth Department of Human Services and Health: The interim
evaluation of the organised appraoch to preventing cancer of the cervix
1991–95: Report of the Evaluation Steering Commitee. Canberra:
Commonwealth of Australia; 1995.
33. Australia Bureau of Statistics: Consumer price index, June Quarter 1993.
Canberra: Commonwealth of Australia; 1993.
34. Australia Bureau of Statistics: Consumer price index, June Quarter 2011.
Canberra: Commonwealth of Australia; 2011.
35. Australian Institute of Health and Welfare (AIHW): Public health expenditure
in Australia, 2007–2008. Health and Welfare Expenditure Series no. 38. Cat. no.
HWE 47. Canberra, Australia: AIHW; 2009.
36. Australian Institute of Health and Welfare: National public health expenditure
report 2005–2006. Health and welfare expenditure series no. 32. Cat. no. HWE
39. Canberra: AIHW; 2008.
37. Australian Institute of Health and Welfare: Health expenditure Australia
2009–10. Health and welfare expenditure series no. 46. Cat. no. HWE 55.
Canberra: AIHW; 2011.
38. Medicare Australia Australian Government: Practice Incentives Program.
Cervical Screening Incentive Guideline - August 2011. Canberra:
Commonwealth of Australia; 2011.
39. Aminisani N: Cervical screening in New South Wales and its relationship to
country of birth and socioeconimics status, PhD Thesis: The University of
Sydney, Sydney School of Public Health, Faculty of Medicine; 2011.
40. Australian Institute of Health and Welfare (AIHW): Cervical Screening in
Australia 2008–2009. Cancer series no. 61. Cat. no. CAN 57. Canberra: AIHW;
2011.
41. Giorgi RP, Ricciardi A, Cohet C, Palazzo F, Furnari G, Valle S, Largeron N,
Federici A: Epidemiology and costs of cervical cancer screening and
cervical dysplasia in Italy. BMC Public Health 2009, 9:71.
42. Bergeron C, Breugelmans JG, Bouee S, Lorans C, Benard S, Remy V: Cervical
cancer screening and associated treatment costs in France. Gynecol
Obstet Fertil 2006, 34:1036–1042.
43. Parliamentary Office of Science and Technology: Postnote: Cervical Cancer.
Available at: www.parliament.uk/briefing-papers/POST-PN-316.pdf.
44. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, De SS,
Naucler P, Lloveras B, Kjaer S, et al: Long term predictive values of
cytology and human papillomavirus testing in cervical cancer screening:
joint European cohort study. BMJ 2008, 337:a1754.
doi:10.1186/1472-6963-12-446
Cite this article as: Lew et al.: Expenditure and resource utilisation for
cervical screening in Australia. BMC Health Services Research 2012 12:446.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
